Business
Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok
HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing
About this update from Zura Bio Limited
[{"type":"text","content":" HENDERSON, Nev.--(BUSINESS WIRE)--\nZura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced two abstracts were accepted and presented at World Allergy Congress (WAC), held December 1 – 3, 2023 in Bangkok, Thailand. The abstracts highlight Zura Bio’s informative research for ZB-168, an anti-IL-7Rα monoclonal antibody with potential across a broad set of indications where the IL-7 or TSLP pathways may be involved, and ZB-880 (torudokimab), a fully human, high affinity monoclonal antibody that neutralizes IL-33 and also has potential for a broad range of indications.\n\n\n“Introducing Zura Bio’s ZB-168 and ZB-880 at World Allergy Congress is an opportunity to share the unique science behind these assets. ZB-168 uniquely inhibits both IL-7 and TSLP, while ZB-880 prevents IL-33 mediated-activation of ST2-dependent and independent inflammation. The unique biology of our assets may give us access to a broad range of biology applicable in a number of autoimmune and inflammatory diseases,” said Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Science at Zura Bio. “We believe these could have applicability in the dermatological, rheumatological, gastrointestinal and respiratory spaces, and we are very excited about taking these development programs forward.”\n\n\nDetails are as follows:\n\n\nAbstract: WAC23-0180\nTitle: Biomarker analysis identifies subset of atopic dermatitis patients that respond to IL-33 blockade\nAuthors: Michael Howell, Ph.D., Jackson Cabell, Brandon Walsh, Ph.D., Someit Sidhu, M.D., Christopher Cabell, M.D.\n\n\nAbstract: WAC23-0179\nTitle: ZB-168 potently inhibits thymic stromal lymphopoietin mediated Inflammation\nAuthors: Christopher Cabell, M.D., Javier Cote-Sierra, Ph.D., Karl Deacon, Ph.D., Someit Sidhu, M.D., Michael Howell, Ph.D.\n\n\nFull session details can be accessed via the WAC program.\n\n\nABOUT ZURA BIO\n\n\nZura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for ZB-106 (tibulizumab), ...